The study modeled the harms and benefits of introducing four-yearly PSA screening for all men aged 55 to 69 versus more targeted checks for those at higher risk of the disease. The researchers concluded that the best approach would be to screen men at a slightly higher genetic risk – nearly half of men in that age group — as this would have the biggest health benefit, preventing deaths from prostate cancer while minimizing unnecessary treatments for harmless tumors.